Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders, Major Depressive Disorder is Suspected to Have the Greatest Burden by 2030,Kynurenine Pathway is Major Route Through Which the Essential Amino Acid Tryptophan is Metabolised and Activated in Time of Stress and Immune Activation.

NCT07771517 | Not Yet Recruiting

• 1 other identifier: Soh-Med--26-7-2MD
• Study Type: observational
• Target: 90
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a case control study including simple random cases of 90 persons, 45 of them have depressive disorders and the other 45 are healthy individuals,age group between 18-60 years old, cases will be recruited from outpatient psychiatric clinic in sohag university hospital, all cases will be exposed to psychological assessment and also laboratory assessment of kynurenine metabolites by using biokits

Conditions

Major Depressive Disorder (MDD)

Keywords

Kynurenine pathway; MDD; Kynurenine pathway in depressive disorders; Depressive disorder; Bipolar disorder; Role of kynurenine pathway and its Metabolites in depressive disorders

Outcome Measures

Primary Outcomes (2)

• Psychological assessment of patients with depressive disorders

  All cases will be subjected to psychological assessment by using structured clinical interview for DSM-V to assess major depressive disorder,bipolar and other depressivedisorders, Hamilton depression rating scale HAN-D to assess MDD, Hamilton anxiety inventory HAM-A to assess anxiety disorders, Montreal cognitive assessment to assess cognitive functions, Pittsburg sleep quality index to assess quality of sleep and detailed family history will be obtained to assess possibility of genetic factors in health relatives to patients with depressive disorders.

  From the enrollment of all cases till three months later

• Detect abnormalities in kynurenine pathway in patients with depressive disorders

  Blood samples will be collected from patients and healthy control cases in microbiology laboratory in Sohag university hospital; by using biokits for kynurenine to measure kynurenine level in nanomolar to low micromolar in liter, Add a tryptophan measure outcome to measure tryptophan level in micromol per liter Add a quinolinic acid measure outcome to measure quinolinic acid level in microgram per milliliter by ELISA

  From the time of enrollment till 3 months later

Eligibility Criteria

• Age: 18 Years - 18 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Patients with age group between 18: 60 years old and all cases are drug free of at least 4 months

You may qualify if:

• age group 18: 60 years old
• cases are drug free of at least 4 months

You may not qualify if:

• patients with comorbid other psychiatric disorders( SUD,anxiety)
• patients with IQ below 90
• patients with psychotic features
• patients with postpartum depression
• patients with chronic medical illness that might affect immune function
• patients under treatment with immune modulating therapy

Sponsors & Collaborators

• Sohag University: lead

MeSH Terms

Conditions

Depressive Disorder, Major; Depressive Disorder; Bipolar Disorder

Condition Hierarchy (Ancestors)

Mood Disorders; Mental Disorders; Bipolar and Related Disorders

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer at Sohag university hospital

Study Record Dates

• First Submitted: August 3, 2026
• First Posted: August 18, 2026
• Study Start (Estimated): March 14, 2027
• Primary Completion (Estimated): August 20, 2028
• Study Completion (Estimated): May 20, 2029
• Last Updated: August 20, 2026

Record last verified: 2026-08